Which medications can protect the kidneys, heart and blood vessels?

Photo of someone taking tablets
PantherMedia / Ramona Heim

Medication can stop chronic kidney disease from getting worse. Blood-pressure-lowering medicine is particularly important.

Medication can help to stop or slow down the progress of chronic kidney disease and prevent consequences of kidney disease (complications) such as heart attacks. The medication options for someone with chronic kidney disease will be influenced by things like other medical conditions that they have and their individual risk of complications.

Blood-pressure-lowering drugs

The decision of whether to reduce blood pressure levels in someone who has chronic kidney disease will depend on

  • how high their blood pressure is (when untreated),
  • whether they have diabetes, and
  • how much protein is in their urine (albumin level).

A person with normal blood pressure who doesn’t have diabetes and hardly has any albumin in their urine will be able to get by without using any blood-pressure-lowering medication. But people who have high blood pressure, diabetes or high levels of albumin in their urine are advised to have treatment with ACE inhibitors (angiotensin-converting enzyme inhibitors) or sartans (angiotensin receptor blockers). In people who have diabetes, blood-sugar-lowering medication is also important.

An analysis of 119 studies involving over 64,000 participants with advanced kidney disease has shown that ACE inhibitors and sartans offer several advantages: Compared with other blood-pressure-lowering medications (like beta blockers), ACE inhibitors or sartans were more effective at reducing the risk of complete kidney failure. They also reduced the risk of cardiovascular diseases such as heart attacks or strokes.

There is no proof that taking an ACE inhibitor together with a sartan offers any advantages in people with chronic kidney disease. This combination may be more likely to do harm.

Cholesterol-lowering medications (statins)

Statins are medications that lower in the blood. They may be prescribed after a , for example, because they can then help prevent more problems affecting the heart or blood vessels and increase life expectancy. Studies suggest that this may also be the case in people with chronic kidney disease who do not yet need dialysis. So these people are usually advised to start taking . They will usually carry on taking if dialysis becomes necessary later on.

It’s still not clear whether can also slow down the progression of kidney disease. It’s also not absolutely clear whether have any benefits if people only start taking them once dialysis has already begun.

Anti-clotting medication such as ASA

Medications that reduce the blood’s ability to clot are called anticoagulants or blood thinners. They include acetylsalicylic acid (ASA – the drug in medicines like Aspirin). Anti-clotting medication can prevent heart attacks and strokes, but it can also cause bleeding.

So the benefits and harms of anti-clotting medications always need to be considered carefully. Taking anti-clotting medications may do more harm than good in some people with mild kidney disease. But these medications can be a good idea in patients who have a high risk of , for example if they also have coronary artery disease.

Urate-lowering therapy

Uric acid salts (urate) can build up in the blood as a result of poor kidney function. This may lead to bouts of gout. Medications like allopurinol lower the levels of uric acid to help prevent gout, but they may also cause side effects like rashes or nausea. Initial studies suggest that allopurinol can slow down the progression of chronic kidney disease and prevent cardiovascular complications. More research is needed to confirm this, though.

Do dietary supplements help?

It is highly questionable whether over-the-counter dietary supplements can help people with chronic kidney disease. For instance, it has been proven that antioxidants such as vitamin E supplements can neither increase life expectancy in people with chronic kidney disease nor prevent complications like heart attacks or strokes. There is also no proof that these medications can slow down the progression of the disease or help in certain people (such as dialysis patients). This is true for fish oil and omega-3 fatty acid supplements, too.

Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R et al. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technol Assess 2014; 18(40): 1-77, v-vi.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012; (10): CD008176.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). January 2013.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. December 2012.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2013 Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. November 2013.

Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; (4): CD008834.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; (5): CD007784.

Sanguankeo A, Upala S, Cheungpasitporn W, Ungprasert P, Knight EL. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLoS ONE 2015; 10(7): e0132970.

Sun L, Zou L, Chen M, Liu B. Meta-analysis of statin therapy in maintenance dialysis patients. Ren Fail 2015; 37(7): 1149-1156.

Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016; 67(5): 728-741.

Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016; 105: 74-83.

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on March 8, 2018
Next planned update: 2021


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.